Abstract:Objectives Early placement of transjugular intrahepatic portosystemic shunt (TIPS) has been shown to improve survival in high-risk patients (Child-Pugh B plus active bleeding at endoscopy or Child-Pugh C 10-13) with cirrhosis and acute variceal bleeding (AVB). However, early TIPS criteria may overestimate the mortality risk in a significant proportion of patients, and the survival benefit conferred by early TIPS in such patients has been questioned. Alternative criteria have been proposed to refine the criteria used to identify candidates for early TIPS. Nevertheless, the true survival benefit provided (or not) by early TIPS compared with standard treatment in the different risk categories has not been investigated in specifically designed comparative studies. Design We collected data on 1425 consecutive patients with cirrhosis and AVB who were admitted to 12 university hospitals in China between December 2010 and June 2016. Of these, 206 patients received early TIPS, and 1219 patients received standard treatment. The Fine and Gray competing risk regression model was used to compare the outcomes between the two groups that were stratified based on the currently available risk stratification systems after adjusting for liver disease severity and other potential confounders. Results Overall, early TIPS was associated with an 80% relative risk reduction (RRR) in mortality at 6 weeks (adjusted HR=0.20; 95% CI : 0.10 to 044; p<0.001) and 51% RRR at 1 year (adjusted HR=0.49, 95% CI : 0.32 to 0.73; p<0.001) compared with standard treatment. In stratification analyses, the RRRs in mortality did not significantly differ among the risk categories. However, the absolute risk reductions (ARRs) of mortality were more pronounced in high-risk patients. The ARRs at 6 weeks were -2.1%, -10.2% and -32.4% in Model for End-stage Liver Disease (MELD) <= 11, 12-18 and >= 19 patients and were -1.5%, -9.1% and -23.2% in Child-Pugh A, B and C patients, respectively (interaction tests, p<0.001 for both criteria). The ARRs for mortality at 1 year were -1.7%, -5.4% and -32.7% in MELD <= 11, 12-18 and >= 19 patients, respectively, and -3.6%, -5.2% and -20.3% in Child-Pugh A, B and C patients, respectively (interaction tests, p<0.001 for both criteria). After adjusting for liver disease severity and other potential confounders, a survival benefit was observed in MELD >= 19 or Child-Pugh C patients but not in MELD <= 11 or Child-Pugh A patients. In MELD 12-18 patients, a survival benefit was observed within 6 weeks but not at 1 year. In Child-Pugh B patients, a survival benefit was observed in those with active bleeding but not those without active bleeding. However, the evaluation of active bleeding was associated with a high interobserver variability. Furthermore, early TIPS was associated with a significantly reduced incidence of failure to control bleeding or rebleeding and new or worsening ascites, without increasing the risk of overt hepatic encephalopathy. Conclusions Early TIPS was associated with improved survival in patients with MELD >= 19 or Child-Pugh C cirrhosis but not in patients with MELD <= 11 or Child-Pugh A cirrhosis. For MELD 12-18 or ChildPugh B patients, future studies addressing optimal selection criteria for early TIPS remain highly warranted.

Clinical characteristics and natural history of porto‐sinusoidal vascular disease: A cohort study of 234 patients in China

Porto-Sinusoidal Vascular Disease: A New Nomenclature Different from Idiopathic Non-Cirrhotic Portal Hypertension

Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome.

Prospective evaluation of patients with non‐cirrhotic portal hypertension: A single centre study

Application of liver biopsy in etiological diagnosis of unexplained portal hypertension: Porto-sinusoidal vascular disease should not be ignored

Dissociation in hepatic vein pressure gradient, liver stiffness measurement and complications in histological subtypes of porto-sinusoidal vascular disease

Association between gut-derived endotoxins and porto-sinusoidal vascular disorder with portal hypertension

[Clinical Characteristics of Hepatic Sinusoidal Obstruction Syndrome: Analysis of 8 Cases].

Prevalence, clinical characteristics, and outcomes of spontaneous portosystemic shunt in patients with hepatitis B-related cirrhosis: A multicenter study from China

Clinically significant portal hypertension in patients with primary biliary cholangitis: Clinicopathological features and prognostic value

Link between persistent, unexplained gamma-glutamyltransferase elevation and porto-sinusoidal vascular disorder

Genetic predisposition to porto-sinusoidal vascular disorder

Clinical Analysis of Sinistral Portal Hypertension

Diagnostic challenges in non-cirrhotic portal hypertension - porto sinusoidal vascular disease

Porto-sinusoidal vascular disease with portal hypertension versus liver cirrhosis: differences in imaging features on CT and hepatobiliary contrast-enhanced MRI

Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations

Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

The portal hypertension syndrome: etiology, classification, relevance, and animal models

Porto-sinusoidal vascular disorder in surgical candidates for liver metastases: Prevalence, non-invasive diagnosis, and burden on surgical outcomes

Identifying Optimal Candidates for Early TIPS among Patients with Cirrhosis and Acute Variceal Bleeding: a Multicentre Observational Study